s c i e n c e q u a l i t y i n n o v a t i o n

This presentation may contain certain statements including, without limitation, the words “may”, “plan”, “will”,“estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “benefits”, “leading to”,“possible”, “is subject to” and other similar expressions which may constitute “forward-looking statements”within the meaning of applicable securities laws.

Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to anumber of risks and uncertainties that could cause actual results to differ materially from those anticipated.Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sellour products including our novel multiplexing technologies and detection platforms; our ability to maintain anytechnical or product advantages; the success of our Diagnostic Tools and Services business and our intent tobuild near-term revenue streams from this business; the successful regulatory filing and receipt of regulatoryapprovals for our later stage quantitative diagnostic kits; adverse changes in general economic conditions;international risk and currency exchange fluctuations; competitor activity; technology changes; regulatoryapprovals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in thefuture.

Such statements, risks and uncertainties are detailed in the Company’s ongoing filings with the securitiesregulatory authorities, and are available to the public at www.sedar.com. The Company undertakes noobligation to publicly update or revise any forward-looking statements either as a result of new information,future events or otherwise, except as required by applicable securities laws.

FORWARD LOOKING STATEMENTS

2

3

BioPharma Drug Developers & Other Diagnostic Companies with novel tests

A DIAGNOSTIC TOOLS COMPANY OFFERING MULTIPLEXED DX TESTS AND AUTOMATED

SYSTEMS TO MEET THE UNMET NEEDS OF

science quality innovation

Proven multiplexing technology – more results, fewer tests run

Growing list of established diagnostics and global biopharma customers

Technical Superiority

Very high levels of customer satisfaction

ISO 13485 compliant development and manufacturing – trust

Achieving significant cost reductions in their core business

EXPERIENCED EXECUTIVE TEAM

Name Title Previous Affiliations

Andrew Morris CEO

Eric Brouwer CSO

Russ Peloquin VP, Sales & Marketing

Aye Nyein San VP Engineering

Patricia Lie VP Finance TD Canada Trust PwC

Peter Lea Founder 45 Publications; 40 Patents

BOARD OF DIRECTORS

Name Title Affiliations

Clive

BeddoeChairman

Hanover Group of Companies

Gerald

Connor

Board Member

Wilmot

MatthewsBoard Member

Claude Ricks Chairman, Audit Committee

Eric

Schneider

Board Member

Andrew

MorrisBoard Member, CEO

MULTIPLEXING

6

mul·ti·plex ---- verb ---- /‘məl-tē -, pleks/-to detect multiple analytes from a single biological specimen

one wellone unit of effortmultiple results

the pain is cost, the cure is multiplexing and automated analyzers from SQI

using only 15 minutes of labour, our products and systems deliver full panels of over 7,000 quantified results

reducing labour costs by > 90%maintaining quality and performance

in every result

7

SIGNIFICANT LABOUR AND TIME SAVINGS

Save time and reduce costs, with superior technical performance

Standard ELISA(manual operation)

sqidliteTM

50 Minutes / Patient 30 Seconds / Patient

10-X

8

SIGNIFICANT LABOUR AND TIME SAVINGS – MATH

and, the sqidlite is super easy to use

Standard ELISA(manual operation) sqidliteTM

43 plex biomarker panel

100,000 patient samples

43 samples / patient

86 if using duplicates

89,583 ELISA Kits

3,733 days of labour

1 sample / patient

no duplicates needed

1,042 SQI Kits

34 days of labour on 2 sqidlites

Focus on Two Major Dx Markets

9

40%

50%

10%

Drug Development Testing

Global Pharma

Gobal Biotech

Medium Pharma

40%

40%

10%

10%

Diagnostic Tests

Global Animal HealthDx

Human Molecular Dx

Human Protein Dx

SQD IVD -autoimmune, etc.

custom and off-the-shelf tests for drug development testing

safety & efficacy tests are large % of total R&D budgets & are addressable by SQI tech

$11B in North America

we take Dx operators’ existing single test products and multiplex them

Human and Animal Health addressable markets

Human - $4B for Dx immunoassays / $9B for Dx molecular tests in North America

Animal Health - $1B consumables market

$11B $14B

10

CURRENT CUSTOMERS & SALES FUNNEL

Customer

Count Customer Description Alternate Name / Detail Commercial Status

1 GD-Biosciences PULS 7-plex predictive panel Generating Revenue, 1 sqidlite, Second Order Shipped

2 DNA Sepsis Customer Sepsis pathogen detection Generating revenue (2 sqidlites)

3 Big Pharma PK Generating revenue (1 sqidlite under service contract)

4 Big Pharma; SQI as CRO GM-CSF Generating revenue; Prd Dev done; awaiting patient samples

5 IRX Pharma Quality Control Kits Generating review (1 sqid-X); 2 orders shipped

6 Big Biotech ; SQI as CRO ADA Generating Revenu; Prod Dev Complete; waiting for primate samples

7 Big Biotech; SQI as CRO ADA Prod Dev Complete -company sold - pause

Sales Funnel

Near Term Prospects

8 Direct to Consumer Dx Celiac / RA / Men's health Contracting

9 Partnership: Lung Transplant Dx 8-plex MDx and PoC MDx Green Light to proceed; Term Sheet and Quote pending acceptance

10 CRO Take out MSD - cytokines, ADA Work planning

Animal Dx (same customer as #2) Bovine Mastitis Selling small volumes of kits

11 Big Biotech Cytokine Samples to be sent 0x/2018

12 63X Cytokine Panel Peprotech-Stanford-SQI Work planning

13 Partnership: Lupus Nephritis Dx J Winter / 6-plex Work planning

Big Pharma (same customer as #3) Xplex / Streptavidin / NAb On hold

RECENT (CUSTOMER) ANNOUNCEMENTS

GD Biosciences PULS cardiac panel validation completed Feb 27 – their customers include Cleveland Heartlabs (acquired by Quest), LifeLabs, Cedar Sinai, and others

Global Biotech Signed – Jan 17

7 Plex PULS panel for cardiac markers completed, sqidlite installed Nov 30

Global Pharma Signed – Nov 20

Over-subscribed financing closes – Dec 20

SQI Partners with McMaster to co-develop “instant immunoassay” chip – Jul 24

SQI Diagnostics announces commercial contract with global biotechnology company – Jul 18

SQI Sells sqid-X system to IRX Therapeutics

12

5 YEAR FINANCIAL VIEW

Fiscal YE 2015 [A] 2016 [A] 2017 [A] 2018 [E] 2019 [E]

# Platforms 1 2 5+ 10+ 20+

$ millions

Revenue 0.6 1.6 1 3-4 10+

Op Expenses 6.4 5.6 6 6.5 7

Cash Flow Positive Exiting 2018

COMPANY SNAPSHOT

13

TSX-V :SQD

Traded on OTCQ :SQIDF

Shares outstanding: 135M

Warrants: 59M

Stock Options:

Market Cap: ~$24M

Insider ownership ~ 66%

24 Jun to 24 Jan trading volume = 34M

VWAP = $0.17

CONTACT INFORMATION:

SQI DIAGNOSTICS INC.

36 METEOR DRIVE

TORONTO, CANADA M9W 1A4

IR@SQIDIAGNOSTICS.COM/AMORRIS@SQIDIAGNOSTICS.COM

416-674-9500 /X229